Clinical trials for Autosomal systemic lupus erythematosus
38 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07447986To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusHangzhou Sumgen Biotech Co., Ltd.
- RECRUITINGPhase 1NCT07363590A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPhase 3NCT07201129A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentViatris Innovation GmbH · PI: Clinical Trials
- RECRUITINGPhase 1NCT07276958A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)Eli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
- RECRUITINGPHASE1, PHASE2NCT07348055A Study of GR1803 in Systemic Lupus ErythematosusGenrix (Shanghai) Biopharmaceutical Co., Ltd.
- RECRUITINGPhase 1NCT07318259Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT07000110Anifrolumab Malignancy and Serious Infections StudyAstraZeneca
- RECRUITINGPhase 1NCT07331467Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT07175285A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 ImmunosuppressantsBristol-Myers Squibb · PI: Bristol Myers Squibb
- RECRUITINGPhase 1NCT07215663Clinical Study of Cizutamig in Systemic Lupus ErythematosusCandid Therapeutics
- RECRUITINGPhase 1NCT06977724A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)AbbVie · PI: ABBVIE INC.
- RECRUITINGPHASE1, PHASE2NCT07041801Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem CellsShenzhen Beike Bio-Technology Co., Ltd.
- RECRUITINGN/ANCT06713187Interleukin23 in Systemic LupusSohag University
- RECRUITINGPHASE1, PHASE2NCT06897930A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLEAstraZeneca
- RECRUITINGEarly Phase 1NCT06920433UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus ErythematosusZhejiang University
- RECRUITINGNCT06673043Anifrolumab Real-world Treatment Outcomes in Systemic Lupus ErythematosusAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT06841042A Study of SCTB35 in Patients with Systemic Lupus ErythematosusSinocelltech Ltd.
- RECRUITINGPhase 3NCT06617325A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusUCB Biopharma SRL · PI: UCB Cares
- RECRUITINGNCT06314282INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World UseAstraZeneca
- RECRUITINGNCT06527872Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LNGlaxoSmithKline · PI: GSK Clinical Trials
- RECRUITINGPHASE1, PHASE2NCT06625671A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE ParticipantsDualityBio Inc. · PI: Lily Hu
- RECRUITINGPHASE1, PHASE2NCT06530849A Study of GC012F Injection in Subjects With Refractory Systemic Lupus ErythematosusGracell Biotechnologies (Shanghai) Co., Ltd.
- ENROLLING BY INVITATIONPhase 3NCT06475742Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusViatris Innovation GmbH · PI: Clinical Trials
- RECRUITINGN/ANCT06513429IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)Peking University Third Hospital
- ACTIVE NOT RECRUITINGPhase 1NCT06265220AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusArtiva Biotherapeutics, Inc. · PI: Michael Saddekni, M.D., PgDip, BCMAS
- RECRUITINGNCT06167174Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics AnalysisChinese SLE Treatment And Research Group · PI: Xinping Tian, MD
- RECRUITINGNCT07215754Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE PatientsUniversity of Pisa
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05938725KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisKyverna Therapeutics · PI: MD
- ACTIVE NOT RECRUITINGPhase 3NCT05624749Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 3NCT05639114Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGN/ANCT05737732The Ambient Light Multiple Myeloma StudyIcahn School of Medicine at Mount Sinai · PI: Mariana Figueiro, PhD
- ACTIVE NOT RECRUITINGNCT05590390Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial)Azienda Ospedaliera Universitaria Integrata Verona · PI: Maurizio Rossini, MD, PhD
- RECRUITINGNCT05470569Argentinian Prospective Registry of Patients With LupusSociedad Argentina de Reumatologia
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06015230Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLEGenrix (Shanghai) Biopharmaceutical Co., Ltd. · PI: xiaofeng zeng, PHD
- ACTIVE NOT RECRUITINGPhase 3NCT04895241A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusBiogen · PI: Medical Director
- ACTIVE NOT RECRUITINGPhase 3NCT04582136Efficacy and Safety of Sirolimus in Active Systemic Lupus ErythematosusChinese SLE Treatment And Research Group · PI: Xiaofeng Zeng, MD
- ACTIVE NOT RECRUITINGN/ANCT02653287Lupus Intervention for Fatigue TrialNorthwestern University · PI: Rosalind Ramsey-Goldman, MD, DrPH
- RECRUITINGNCT03138941Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific RegionMonash University · PI: Eric Morand